Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Sensitive LC-MS/MS method for quantification of rivaroxaban in plasma: Application to pharmacokinetic studies

Full text
de Oliveira, Alexandre Cavenatti [1] ; Davanco, Marcelo Gomes [1] ; de Campos, Daniel Rossi [1] ; Godoy Sanches, Pedro Henrique [2] ; Goncalves Cirino, Joao Pedro [2] ; Carvalho, Patricia de Oliveira [2, 1] ; Antonio, Marcia Aparecida [1, 3] ; Coelho, Edvaldo Capobiango [3] ; Porcari, Andreia M. [2, 1]
Total Authors: 9
[1] Univ Sao Francisco, Hlth Sci Postgrad Program, Ave Sao Francisco de Assis 218, BR-12916900 Braganca Paulista, SP - Brazil
[2] Univ Sao Francisco, Lab Multidisciplinary Res, Braganca Paulista, SP - Brazil
[3] Univ Sao Francisco, Integrated Unit Pharmacol & Gastroenterol UNIFAG, Braganca Paulista, SP - Brazil
Total Affiliations: 3
Document type: Journal article
Source: BIOMEDICAL CHROMATOGRAPHY; v. 35, n. 9 SEP 2021.
Web of Science Citations: 0

Rivaroxaban is an anticoagulant (orally active direct Xa inhibitor) considered to reduce the risk of stroke and systemic embolism and treat deep vein thrombosis, pulmonary embolism, and other cardiovascular complications. Bioanalytical methods for rivaroxaban quantification in plasma are necessary for application in pharmacokinetic studies, as well as in drug therapeutic monitoring. In this work, we developed and validated a sensitive bioanalytical method using LC-MS/MS for rivaroxaban quantification in human plasma using an one-step liquid-liquid extraction. The linear concentration range was 1-600 ng/mL. The bioanalytical method was also applied to pharmacokinetic studies in healthy volunteers under fasting and fed conditions. The results demonstrated that the method is rapid, sensitive, and adequate for application in pharmacokinetic studies. (AU)

FAPESP's process: 19/04314-6 - Imaging and mass spectrometry-based metabolomics applied to the study of drug resistance in neoadjuvant therapy for breast cancer: the search for a predictive test
Grantee:Andréia de Melo Porcari
Support type: Regular Research Grants